Table 1:
Characteristics of uveitic eyes (E) at entry into the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.
| Characteristic | Anterior E=4525 |
Intermediate E=1658 |
Posterior E=1605 |
Panuveitis E=1011 |
|
|---|---|---|---|---|---|
| Age | <18 | 603 (13%) | 295 (18%) | 84 (5%) | 122 (12%) |
| 18–25 | 287 (6%) | 206 (12%) | 124 (8%) | 103 (10%) | |
| 26–35 | 741 (16%) | 375 (23%) | 295 (18%) | 185 (18%) | |
| 36–45 | 981 (22%) | 339 (20%) | 346 (22%) | 212 (21%) | |
| 46–55 | 929 (21%) | 228 (14%) | 352 (22%) | 164 (16%) | |
| 56–65 | 570 (13%) | 131 (8%) | 207 (13%) | 100 (10%) | |
| >65 | 414 (9%) | 84 (5%) | 197 (12%) | 125 (12%) | |
| Gender | Male | 1544 (34%) | 613 (37%) | 623 (39%) | 317 (31%) |
| Race/Ethnicity* | White | 3238 (72%) | 1385 (84%) | 1288 (80%) | 546 (54%) |
| Black | 807 (18%) | 110 (7%) | 120 (7%) | 280 (28%) | |
| Hispanic | 139 (3%) | 71 (4%) | 82 (5%) | 88 (9%) | |
| Other | 341 (8%) | 92 (6%) | 115 (7%) | 97 (10%) | |
| Smoking | Never | 3045 (67%) | 802 (48%) | 792 (49%) | 474 (47%) |
| Past | 492 (11%) | 141 (9%) | 173 (11%) | 123 (12%) | |
| Current | 617 (14%) | 383 (23%) | 283 (18%) | 203 (20%) | |
| Unknown† | 371 (8%) | 332 (20%) | 357 (22%) | 211 (21%) | |
| Behçet Disease | 30 (1%) | 26 (2%) | 94 (6%) | 74 (7%) | |
| Sarcoidosis | 294 (6%) | 94 (6%) | 96 (6%) | 117 (12%) | |
| Juvenile Idiopathic Arthritis (JIA) | 370 (8%) | 15 (1%) | 16 (1%) | 10 (1%) | |
| Spondyloarthropathy | 380 (8%) | 13 (1%) | 17 (1%) | 8 (1%) | |
| Inflammatory Bowel Disease (IBD)** | 175 (4%) | 24 (1%) | 15 (1%) | 15 (1%) | |
| Other Systemic Inflammatory Disease | 163 (4%) | 89 (5%) | 81 (5%) | 34 (3%) | |
| Prior Cataract Surgery | Never | 4001 (88%) | 1520 (92%) | 1444 (90%) | 820 (81%) |
| Prior to Baseline | 524 (12%) | 138 (8%) | 161 (10%) | 191 (19%) | |
| During Follow-up***** | n/a | ||||
| Prior Glaucoma Surgery | 109 (2%) | 18 (1%) | 19 (1%) | 27 (3%) | |
| Prior Retinal Detachment Surgery | 28 (1%) | 15 (1%) | 17 (1%) | 18 (2%) | |
| Prior Pars Plana Vitrectomy (not for retinal detachment) | 83 (2%) | 56 (3%) | 48 (3%) | 64 (6%) | |
| Duration of Uveitis Prior to Presentation for Tertiary Uveitis Care |
≤6 months | 1473 (33%) | 541 (33%) | 659 (41%) | 344 (34%) |
| >6 months to 2 years | 985 (22%) | 377 (23%) | 381 (24%) | 266 (26%) | |
| >2 to 5 years | 786 (17%) | 352 (21%) | 284 (18%) | 170 (17%) | |
| ≥5 years | 1281 (28%) | 388 (23%) | 281 (18%) | 231 (23%) | |
| Anterior Chamber Cells | Quiet | 2342 (52%) | 1093 (66%) | 1283 (80%) | 427 (42%) |
| 0.5+ | 768 (17%) | 302 (18%) | 181 (11%) | 219 (22%) | |
| 1+ | 656 (14%) | 167 (10%) | 63 (4%) | 157 (16%) | |
| 2+ or worse | 759 (17%) | 96 (6%) | 78 (5%) | 208 (21%) | |
| Vitreous Cells | Quiet | 3295 (73%) | 460 (28%) | 825 (51%) | 347 (34%) |
| 0.5+ | 488 (11%) | 264 (16%) | 256 (16%) | 182 (18%) | |
| 1+ | 464 (10%) | 440 (27%) | 280 (17%) | 228 (23%) | |
| 2+ or worse | 278 (6%) | 494 (30%) | 244 (15%) | 254 (25%) | |
| Vitreous Haze*** | Quiet | 3943 (87%) | 1055 (64%) | 1259 (78%) | 624 (62%) |
| 1+ | 207 (5%) | 340 (21%) | 201 (13%) | 208 (21%) | |
| 2+ | 89 (2%) | 139 (8%) | 57 (4%) | 65 (6%) | |
| 3+ or worse | 20 (0%) | 36 (2%) | 12 (1%) | 39 (4%) | |
| Missing† | 266 (6%) | 88 (5%) | 76 (5%) | 75 (7%) | |
| Intraocular Pressure | ≤5 mm Hg | 60 (1%) | 3 (0%) | 8 (0%) | 27 (3%) |
| 6–23 mm Hg | 4010 (89%) | 1474 (89%) | 1424 (89%) | 835 (83%) | |
| 24–29 mm Hg | 201 (4%) | 50 (3%) | 46 (3%) | 42 (4%) | |
| ≥30 | 120 (3%) | 24 (1%) | 27 (2%) | 42 (4%) | |
| Missing† | 134 (3%) | 107 (6%) | 100 (6%) | 65 (6%) | |
| Posterior Synechiae, Any | 874 (19%) | 142 (9%) | 71 (4%) | 198 (20%) | |
| Peripheral Anterior Synechiae, Any | 179 (4%) | 32 (2%) | 13 (1%) | 48 (5%) | |
| Band Keratopathy, Any | No | 3481 (77%) | 1390 (84%) | 1393 (87%) | 823 (81%) |
| Yes | 147 (3%) | 37 (2%) | 20 (1%) | 36 (4%) | |
| Missing† | 897 (20%) | 231 (14%) | 192 (12%) | 152 (15%) | |
| Macular Edema | 376 (8%) | 502 (30%) | 256 (16%) | 175 (17%) | |
| Epiretinal Membrane | 164 (4%) | 110 (7%) | 117 (7%) | 87 (9%) | |
| Choroidal Neovascularization | 1 (0%) | 0 (0%) | 62 (4%) | 11 (1%) | |
| Snowbanking**** | 7 (0%) | 376 (23%) | 2 (0%) | 7 (1%) | |
| Retinal Vascular Sheathing | 66 (1%) | 178 (11%) | 321 (20%) | 145 (14%) | |
| Retinal Vascular Occlusion | 1 (0%) | 4 (0%) | 53 (3%) | 4 (0%) | |
Patients with any missing data at baseline were generally not included in the analysis, but band keratopathy (17%), smoking status (14%), intraocular pressure (IOP, 5%), and vitreous haze (6%) were missing enough baseline measurements to warrant respective separate missing categories
Hispanic includes all patients with Hispanic ethnicity
IBD includes ulcerative colitis and Crohn’s disease
0.5+ was not used for vitreous haze due to a database error; it was instead coded as either Quiet or 1+
Snowbanking may have reflected either active exudation or residual fibrosis
By definition no patients could have had cataract surgery during follow-up before beginning follow-up; 206 (2.3%) of the eyes had cataract surgery performed during follow-up